Mostrar el registro sencillo del ítem
dc.contributor.author | Krstić, Luna | |
dc.contributor.author | González García, María Jesús | |
dc.contributor.author | Diebold Luque, María Yolanda | |
dc.date.accessioned | 2022-09-26T08:33:06Z | |
dc.date.available | 2022-09-26T08:33:06Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Molecules, 2021,Vol. 26, Nº.2, 370, 26 pp. | es |
dc.identifier.issn | 1420-3049 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/55631 | |
dc.description | Producción Científica | es |
dc.description.abstract | Nature has become one of the main sources of exploration for researchers that search for new potential molecules to be used in therapy. Polyphenols are emerging as a class of compounds that have attracted the attention of pharmaceutical and biomedical scientists. Thanks to their structural peculiarities, polyphenolic compounds are characterized as good scavengers of free radical species. This, among other medicinal effects, permits them to interfere with different molecular pathways that are involved in the inflammatory process. Unfortunately, many compounds of this class possess low solubility in aqueous solvents and low stability. Ocular pathologies are spread worldwide. It is estimated that every individual at least once in their lifetime experiences some kind of eye disorder. Oxidative stress or inflammatory processes are the basic etiological mechanisms of many ocular pathologies. A variety of polyphenolic compounds have been proved to be efficient in suppressing some of the indicators of these pathologies in in vitro and in vivo models. Further application of polyphenolic compounds in ocular therapy lacks an adequate formulation approach. Therefore, more emphasis should be put in advanced delivery strategies that will overcome the limits of the delivery site as well as the ones related to the polyphenols in use. This review analyzes different drug delivery strategies that are employed for the formulation of polyphenolic compounds when used to treat ocular pathologies related to oxidative stress and inflammation. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Polyphenols | es |
dc.subject | Farmacología ocular | es |
dc.subject | Oxidative stress | es |
dc.subject | Antioxidantes | es |
dc.subject | Inflammation | es |
dc.title | Ocular delivery of polyphenols: meeting the unmet needs | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2021 The Authors | es |
dc.identifier.doi | 10.3390/molecules26020370 | es |
dc.relation.publisherversion | https://www.mdpi.com/1420-3049/26/2/370 | es |
dc.identifier.publicationfirstpage | 1 | es |
dc.identifier.publicationissue | 2 | es |
dc.identifier.publicationlastpage | 26 | es |
dc.identifier.publicationtitle | Molecules | es |
dc.identifier.publicationvolume | 26 | es |
dc.peerreviewed | SI | es |
dc.description.project | Ministerio de Ciencia, Innovación y Universidades - Fondo Europeo de Desarrollo Regional (RTI2018-094071-B-C21) | es |
dc.description.project | European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Initial Training Network (ITN) “IT-DED3” (H2020-MSCA-ITN-2017) grant agreement No. 765608 | es |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/765608 | |
dc.identifier.essn | 1420-3049 | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 3201.09 Oftalmología | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Atribución 4.0 Internacional